PARP1 and colonic neoplasm: Based on these findings, and the fact that PARP inhibitors disrupt BER, we then discovered that small molecule PARP inhibitors robustly sensitized MMR-deficient and –proficient colon cancer cells to FdUrd (but not 5-FU).